PMID- 36184821
OWN - NLM
STAT- MEDLINE
DCOM- 20221115
LR  - 20221118
IS  - 2162-3279 (Electronic)
VI  - 12
IP  - 11
DP  - 2022 Nov
TI  - Levetiracetam versus Oxcarbazepine as monotherapy in newly diagnosed focal 
      epilepsy: A systematic review and meta-analysis.
PG  - e2779
LID - 10.1002/brb3.2779 [doi]
LID - e2779
AB  - OBJECTIVE: To compare the efficacy and safety of Levetiracetam (LEV) and 
      Oxcarbazepine (OXC) as monotherapy for the treatment of newly diagnosed focal 
      epilepsy. METHODS: We searched PubMed, Cochrane Library, EMBASE, and Google 
      Scholar from January 1, 2000 to May 11, 2022, with no language restrictions along 
      with The ClinicalTrials.gov website and the WHO International Controlled Trials 
      Registry platforms. We pooled the risk ratio (RR) and corresponding 95% 
      confidence interval (95% CI) for the efficacy and safety outcomes. The quality of 
      included trials was assessed using the Cochrane Collaboration's tool. RESULTS: 
      Two RCTs included a total of 574 newly diagnosed focal epilepsy patients (the LEV 
      group [282 patients] and the OXC group [292 patients]). LEV group when compared 
      with the OXC group had no significant difference in the pooled estimate of 
      seizure freedom at week 24. (RR: 0.81; 95% CI: 0.62-1.05, p = .11). Similarly, 
      there was no significant difference in the pooled estimate of withdrawal due to 
      adverse events (AEs) (RR: 0.87; 95% CI: 0.34-2.23, p = .77). The commonly 
      reported AEs in both trials were dizziness, headache, rash, somnolence, and 
      nasopharyngitis with zero medication-related death and few serious AEs. 
      CONCLUSIONS: LEV is noninferior to OXC in terms of seizure freedom at week 24 and 
      treatment withdrawal rate due to AEs among adults but long-term treatment data is 
      still missing. Future multicentric double-blinded RCTs and real-world studies are 
      of great need.
CI  - (c) 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLC.
FAU - Kharel, Sanjeev
AU  - Kharel S
AUID- ORCID: 0000-0001-9591-3168
AD  - Maharajgunj Medical Campus, Tribhuvan University Institute of Medicine, 
      Maharajgunj, Kathmandu, Nepal.
FAU - Ojha, Rajeev
AU  - Ojha R
AD  - Department of Neurology, Tribhuvan University Teaching Hospital, Maharajgunj, 
      Kathmandu, Nepal.
FAU - Khanal, Surendra
AU  - Khanal S
AD  - Maharajgunj Medical Campus, Tribhuvan University Institute of Medicine, 
      Maharajgunj, Kathmandu, Nepal.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20221002
PL  - United States
TA  - Brain Behav
JT  - Brain and behavior
JID - 101570837
RN  - VZI5B1W380 (Oxcarbazepine)
RN  - 44YRR34555 (Levetiracetam)
RN  - 0 (Anticonvulsants)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Oxcarbazepine/pharmacology/therapeutic use
MH  - Levetiracetam/therapeutic use
MH  - *Anticonvulsants/adverse effects
MH  - *Epilepsies, Partial/drug therapy
PMC - PMC9660411
OTO - NOTNLM
OT  - Levetiracetam
OT  - Oxcarbazepine
OT  - focal epilepsy
OT  - monotherapy
EDAT- 2022/10/04 06:00
MHDA- 2022/11/16 06:00
PMCR- 2022/10/02
CRDT- 2022/10/03 01:12
PHST- 2022/08/14 00:00 [revised]
PHST- 2022/06/08 00:00 [received]
PHST- 2022/09/14 00:00 [accepted]
PHST- 2022/10/04 06:00 [pubmed]
PHST- 2022/11/16 06:00 [medline]
PHST- 2022/10/03 01:12 [entrez]
PHST- 2022/10/02 00:00 [pmc-release]
AID - BRB32779 [pii]
AID - 10.1002/brb3.2779 [doi]
PST - ppublish
SO  - Brain Behav. 2022 Nov;12(11):e2779. doi: 10.1002/brb3.2779. Epub 2022 Oct 2.